Sage Journals: Discover world-class research

Abstract

Multiple sclerosis (MS) was defined as a rare disease in China due to its low prevalence. For a long time, interferon β was the only approved disease-modifying therapy (DMT). Since the first oral DMT was approved in 2018, DMT approval accelerated, and seven DMTs were approved within 5 years. With an increasing number of DMTs being prescribed in clinical practice, it is necessary to discuss the standardized MS treatment algorithms depending on the disease activity and DMT availability. In this review paper, more than 20 Chinese experts in MS have reviewed the therapeutic progress of MS in China and worldwide and discussed algorithms for treating relapsing MS (RMS) based on the available DMTs in China, providing insights for establishing the standardized RMS treatment algorithms in this country.

Plain language summary

Treatment algorithms of relapsing multiple sclerosis in China

In this review paper, more than 20 Chinese experts in MS have reviewed the therapeutic progress of MS in China and worldwide and discussed algorithms for treating relapsing MS (RMS) based on the available DMTs in China, providing insights for establishing the standardized RMS treatment algorithms in this country: 1) CIS and RRMS account for more than 90% of the MS patients and most of them are mild to moderate; 2) MS patients should initiate DMT treatments as soon as the disease has been diagnosed in order to reduce the risk of disease progression; 3) Patients who have been diagnosed with MS should start treatment with fundamental DMTs unless the disease course has been highly active; 4) MAGNIMS score may be a suitable and simplified assessment tool for measuring treatment response to DMTs; 5) Patients treated with corticosteroids and NSIS should be switched to the standardized DMT treatment during remission in accordance with disease activity.

Keywords

China disease-modifying therapy relapsing multiple sclerosis treatment algorithm

Infographic

Introduction

In 2018, multiple sclerosis (MS) was included on the first list of rare diseases in China, which was published by the National Health Council of China. Since then, the approval of disease-modifying therapies (DMTs) and inclusion of the national reimbursement drug list (NRDL) have been accelerated.¹ Before 2018, interferon β (IFN-β) was the only DMT in China, but it is now rarely used in the country. Within 5 years, seven DMTs [glatiramer acetate (GA), teriflunomide, dimethyl fumarate (DMF), fingolimod, siponimod, ozanimod, and ofatumumab] and one symptom management drug (fampridine) were approved by China National Medical Products Administration (NMPA) and marketed in China, as of 31 December 2023. All of these MS drugs, with the exception of GA, were included in the NRDL,² which has greatly improved the prognosis and treatment affordability for patients with MS.

Several categories of DMT have been in clinical use worldwide: IFN-βs, teriflunomide, fumarates, sphingosine-1-phosphate receptor modulators (S1PRMs), anti-CD20 monoclonal antibodies (anti-CD20s), alemtuzumab (anti-CD52 monoclonal antibody), cladribine, and natalizumab (α4-integrin antagonist).^3,4 As a new class of DMTs, Bruton tyrosine kinase inhibitors (BTKi) are under development.⁵ Nowadays, the DMTs used in China have covered most of the different efficacy classes compared with those used in Europe and the US, despite including only eight DMTs. Since these DMTs were approved through an accelerated process, almost all of them, with the exception of teriflunomide, were approved with clinical trial waivers.⁶ With regard to clinical decision-making, it is necessary to discuss to treat MS patients with the appropriate DMTs.

The aims of this review paper are as follows: (1) to summarize the demographic characteristics of MS patients in China; (2) to describe the efficacy of DMTs available in China; and (3) to explore the treatment algorithms of MS based on the DMTs available in China. This manuscript was developed by a group of Chinese experts on MS and have reviewed the literature about the progress of MS treatment both domestically and internationally.

Characteristics of MS patients in China

Demographics

The female:male ratio of MS patients in China is approximately 2:1,^7–14 which is consistent with the global sex ratio, according to the Atlas of MS and MSBase.^15,16 The standardized diagnosis and treatment of MS in China was initiated later than the developed countries.¹⁷ The age at MS diagnosis varies among the different Chinese regions and the different hierarchical levels of hospitals, as there is health inequity. According to a nationwide hospital-based study, the mean age at MS diagnosis was found to be 45.3 years old.⁷ However, in leading neurological centers where there are MS specialists and professional multidisciplinary teams, the mean age at diagnosis is ~30 years old,^8,18,19 which is consistent with data from the Atlas of MS.¹⁵ Therefore, the early diagnosis should be promoted to ensure the early initiation of treatment.

Based on the disease activity and severity of MS in China, mild to moderate MS is more common. More than 90% of patients with MS in China were diagnosed with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS),^8–12,18,20 which is a higher prevalence than in the global data.²¹ In a multicenter retrospective study, 84.2% of MS patients experienced no or one relapse within 1 year, and patients with Expanded Disability Status Scale (EDSS) ⩽3.0 accounted for 59.1% of MS patients.¹² In a cross-sectional survey conducted in different regions of China, 84.0% of the patients had experienced ⩽1 relapse in the previous year.¹³ Moreover, in a prospective, single-center study, EDSS <4.0 accounted for 92.2% of MS patients, 51.2% of the patients completely recovered, and 37.8% partially recovered from the first relapse.¹⁹ Furthermore, in the data from the MSNMOBase registry, 82.5% of patients had ⩽1 relapse in the first 2 years after disease onset.²⁰

DMT usage

There are variations in DMT usage among the different regions of China and among the different hierarchical levels of hospitals. The rate of DMT usage was reported to be more than70% in the leading neurological centers,^8,22 which was higher than the global results (56%), and the findings in Europe (52%) and the Americas (50%), according to the Atlas of MS.²³ However, in some nationwide, multicenter studies, the rate of DMT usage was approximately 30–40%,^9,10,13 which was higher before oral DMT was approved (10%) in China,¹⁴ but still lower than the rates in Australia (64%) and Germany (57%).^24,25 Improving the overall DMT usage in China is key to improve the prognosis of MS patients.

Initiation of RMS treatment in China

MS is a chronic inflammatory and immune-mediated demyelinating disease of the central nervous system (CNS).²⁶ Several hypotheses have been proposed regarding its pathogenesis, including the involvement of Epstein–Barr virus infection, low vitamin D, high latitude, risk genes, smoking, and obesity.²⁷ However, the exact triggers of MS remain unclear, and no treatments have been able to reverse disease progression. The therapeutic strategy involves prevention of relapses and delaying disability progression, and the treatment drugs were named DMT.²⁸ The major mechanisms of action (MoA) of DMTs involve anti-inflammatory and neuroprotective effects through various signaling pathways (Figure 1).²⁹

Figure 1.

Pathology of multiple sclerosis and mechanism of available disease-modifying therapies in China. IFN-β could affect multiple levels of cellular functions to increase the levels of anti-inflammatory agents and reduce the levels of pro-inflammatory cytokines.³⁰ GA is a noninterferon immunomodulator, which has a similar effect as that of IFN-β on multiple levels of cellular functions.³¹ Teriflunomide is a selective, non-competitive, reversible inhibitor of dihydro-orotate dehydrogenase (DHODH), which prevents the proliferation of T- and B-lymphocytes in the periphery.³² DMF is defined as the Nrf2 activator,³³ which could further activate Keap1/Nrf2/ARE signaling pathway to extert its anti-inflammatory and neuroprotective effects.³⁴ S1PRMs have a dual action on S1PRs as the pharmacological antagonists or agonists to prevent the lymphocyte exit into circulation from secondary lymphoid organs.³⁵ Anti-CD20s could directly target CD20⁺ B cells to deplete B cells.³⁶

Before 2018, low-dose steroids, nonspecific immunosuppressant (NSIS), and rituximab were used to treat MS in China during the remitting phase.³⁷ It was impractical to treat MS patients according to disease activity and prognostic factors or to develop personalized treatment strategies. After teriflunomide was approved at the end of 2018, oral DMTs were gradually promoted into clinical practice, and an increasing number of MS patients initiated DMT treatment with more and more approved DMTs.³⁷ To date, eight DMTs have been approved by NMPA (Table 1),¹ and they are all indicated for the treatment of RMS, including CIS, relapsing-remitting multiple sclerosis (RRMS), and active secondary-progressive MS (SPMS), in adults. Fingolimod was also approved to treat pediatric patients (⩾10 years old) with MS. With the different classes of DMTs and the status of NRDL inclusion, the treatment strategy may differ from that in other countries. Against this background, it is now time to explore the treatment algorithm to ensure that neurologists treat MS patients appropriately in China (Figure 2),³⁸ especially physicians who have limited experience in MS diagnosis and treatment.

Table 1.

Pivotal data of disease-modifying therapies approved in China.

DMTs	Dosage	Pivotal data in RCTs
DMTs	Dosage	ARR reduction³	NEDA-3 in core phase
Interferon β-1b	Subcutaneous injection 0.25 mg every other day	versus placebo: ↓34%	–
Glatiramer acetate	Subcutaneous injection 1 ml: 40 mg three times per week 1 ml: 20 mg QD	versus placebo: ↓29%	19.4%³⁹
Teriflunomide	Oral 7 mg or 14 mg QD	versus placebo: ↓32% (14 mg)	23%⁴⁰
Dimethyl fumarate	Oral Titration: 120 mg BID × 7 days Maintenance: 240 mg BID	versus placebo: ↓44% and 53%	26%⁴¹
Fingolimod	Oral 0.5 mg QD	versus placebo: ↓ 54% versus IFNβ-1a: ↓38% (1.25 mg) and 52% (0.5 mg)	33%⁴²
Siponimod	Oral Patients with a CYP2C9 1 * 1 or 1 2 or 2 2* Titration: Day 1–2, 0.25 mg QD; Day 3, 0.50 mg QD; Day 4: 0.75 mg QD; Day 5, 1.25 mg QD. Maintenance: 2 mg QD Patients with a CYP2C9 2 * 3 or 1 3* Titration: Day 1–2, 0.25 QD, Day 3 0.50 mg QD; Day 4 0.75 mg QD Maintenance: 1 mg QD.	versus placebo: ↓55%	–
Ozanimod	Oral Titration: Day 1–4, 0.23 mg QD; Day 5–7, 0.46 mg QD. Maintenance: 0.92 mg QD.	versus IFNβ-1a: ↓48% and 38%	24.6%⁴³
Ofatumumab	Subcutaneous injection Loading dose: Week 0, 1 and 2, 20 mg Maintenance: 20 mg monthly starting at Week 4	versus teriflunomide: ↓ 51% and 58%	37.7%⁴⁴

ARR, annualized relapse rate; BID, twice daily; CIS, clinically isolated syndrome; DMT, disease-modifying therapy; MS, multiple sclerosis; NEDA-3, no evidence of disease activity 3; RCTs, randomized clinical trials; RMS, relapsing forms of MS; RRMS, relapsing-remitting MS; QD, once daily; SPMS, secondary progressive MS.

Figure 2.

Treatment algorithms of relapsing–remitting MS based on the available disease-modifying therapy in China. MS patients should start treatment with fundamental DMTs unless the disease course becomes highly active. MS patients with highly active MS must be treated with high-efficacy therapies. DMF and S1PRMs are recommended to treat patients with MS with an active inflammatory MS. If patients cannot tolerate current DMTs or have some safety concerns, a switch to a DMT with a different mechanism of action but similar efficacy is highly recommended to maximize the clinical benefits and avoid overtreatment. When the patients show a suboptimal response to the current treatment, it should be considered to switch to another DMT with a different MoA or with different efficacy profile depending on the disease activity, which could be assessed using MAGNIMS score: No change of DMT in patients with Score 0; Switching to a DMT with a different MoA and with similar efficacy in patients with Score 1; and switching to a DMT with higher efficacy in patients with Score 2.

Disease activity

In 2013, the US National Multiple Sclerosis Society (NMSS) further modified the MS subtype as ‘not active’ and ‘active’ on the basis of RRMS, SPMS, and primary progressive MS (PPMS) on the basis of 1996 version.^45,46 In clinical practice, MS was often categorized as mild to moderate and (highly) active based on relapse frequency, new magnetic resonance imaging (MRI) findings (mainly T2), EDSS score, and other clinical features.^47–49 There was no clear definition of mild to moderate cases, and the definition of (highly) active disease varied. In 2021, German MS guidelines further categorized MS into mild, active inflammatory, and highly active.⁵⁰ Recently, the Chinese MS guideline (2023 version) was published and clearly defined the highly active disease.⁵¹ In this review paper, to help Chinese physicians better stratify their MS patients, MS is categorized into not active, active inflammatory, and highly active (Figure 2) by using the combination of the NMSS classification, the 2021 German MS guidelines and Chinese MS guideline (2023 version). Patients with mild to moderate disease are divided into those with ‘not active’ and ‘active inflammatory’ MS. Some minor modifications of the definitions are also made based on the clinical situations of MS in China.

Highly active MS is defined as the presence of one or more of the following characteristics^51,52:

(1) EDSS score of 4 within 5 years of MS onset

(2) Poor recovery from the first two relapses in the first year, such as EDSS >1.5 after the second relapse⁵³

(3) Multiple (two or more) relapses with incomplete recovery in the past year

(4) Pyramidal tract involvement (EDSS functional pyramidal score ⩾2) in the first year of the disease⁶

(5) More than two MRI studies showing new or enlarging T2 lesions or gadolinium-enhancing lesions despite treatment

(6) No response to therapy with one or more DMTs for up to 1 year

Active inflammatory MS is defined as the presence of one or more of the following characteristics, irrespective of whether the patients had initiated DMT treatment in the previous 6 months⁵⁰:

(1) at least one clinically objectifiable relapse

(2) one clinical relapse and one or more new MS-type lesions on MRI

(3) on two or more occasions, one or more new MS-type lesions on MRI have occurred in a period of up to 2 years.

‘Not active’ MS is defined as a patient with a relapsing course but no relapses, gadolinium-enhancing activity, or new or unequivocally enlarging T2 lesions, and no EDSS worsening during the assessment period.⁴⁶

Early initiation

The overall DMT usage is still much lower than in the leading neurological centers in China. MS patients should initiate DMT treatments as soon as the disease has been diagnosed in order to reduce the risk of disease progression.^{49,50,54–56} In the BENEFIT trial, initiation of IFNβ-1b treatment in patients with CIS greatly delayed the time to clinically definite MS and ‘McDonald MS’, with reductions of risk by 50% and 44%, respectively.⁵⁷ Additionally, similar results were observed upon treatment with IFNβ-1a (in the CHAMPS, ETOMS, and REFLEX trials) and with teriflunomide (in the TOPIC trial).^58–61 An international observational cohort study has also shown that the early initiation of DMT treatment significantly reduced the risk of RRMS converting to SPMS.^62,63 Adequate evidence supporting early treatment of MS has thus been accumulated.

Treatment options

There have been debates about whether to treat RRMS patients with early high-efficacy therapies (HET) or with the traditional escalation strategy.^64–67 Two large clinical trials, DELIVER-MS (NCT03535298) and TREAT-MS (NCT03500328) that are evaluating the long-term outcomes of early HET versus the escalation approach are currently ongoing. At present, an escalation strategy (Figure 2) is still recommended in many countries.^49,50,54,68 Patients who have been diagnosed with MS should start treatment with fundamental DMT unless the disease course is highly active, as recommended in many countries.^49,50,54,68 The fundamental DMTs are also named platform DMTs,^54,69 which refer to IFNβ-1b, GA, teriflunomide, and DMF. MS patients with highly active MS must be treated with HETs,^47,49,54,70 which refer to anti-CD20s (ofatumumab and rituximab) and S1PRMs (fingolimod, siponimod, and ozanimod) in China. Rituximab has not been indicated to treat patients with MS in China, although a phase III randomized clinical trial (RCT) (RIFUND-MS) proved its efficacy in CIS and RRMS patients.⁷¹ Moreover, in an observational cohort study, rituximab was noninferior to ocrelizumab in terms of disability-related outcomes, but rituximab treatment demonstrated a high risk of relapse.⁷² Furthermore, a retrospective case series (n = 9) revealed that low-dose rituximab (100 mg every 6 months) showed cost-effective results and a good safety profile in Chinese patients with RRMS.⁷³

DMF and S1PRMs can be prescribed for treatment of patients with active inflammatory MS. There were no head-to-head clinical trials comparing the efficacy of teriflunomide, DMF, and S1PRMs. However, real-world studies have provided sufficient evidence for comparison. A nationwide cohort study from Denmark provided Class II evidence that DMF was more effective and had a lower incidence of discontinuation owing to disease breakthrough than teriflunomide in patients with RRMS.⁷⁴ Additionally, similar results were also reported in other real-world studies and meta-analysis. Nevertheless, several other real-world studies demonstrated that the efficacy of teriflunomide was comparable to that of DMF. Moreover, the comparison of DMF and fingolimod was controversial because some studies reported that the efficacy of DMF was comparable to that of fingolimod, whereas only two studies reported that fingolimod was superior to DMF as a second-line treatment. Studies comparing the three DMTs have shown that DMFs exhibited superior efficacy to that of teriflunomide and comparable to that of fingolimod.^75,76 Therefore, DMF and S1PRMs are suitable for treating patients with active inflammatory MS, especially when taking the treatment cost into consideration.

Treatment switching

Treatment response

No treatment can be guaranteed to cure MS. The original goal of treating MS was to delay the disability progression,⁵⁵ which is usually evaluated using the EDSS.⁷⁷ The development of Rio score and modified Rio score aimed to evaluate the treatment response to DMTs (Table 2).^78,79 Rio score was developed with the initial aim of measuring the response to IFN-β treatment (platform treatment), which was then modified in 2013.^78,79 It was found that the modified Rio scores 0, 1, and 2–3 could predict the 3-year probability of disease progression at the rates of 24%, 33%, and 65% (p < 0.001), respectively.⁷⁹ It was also proven that the modified Rio score could predict the response to fingolimod and natalizumab treatment in patients with highly active RRMS.⁸⁰

Table 2.

Treatment response evaluation using MAGNIMS Score and modified Rio Score.

Score	Criteria (In the previous 12 months)	Risk of 3-year treatment failure	Risk of 3-year EDSS worsening	Switching⁶⁴
MAGNIMS Score⁸¹
Score 0	0–2 new T2 lesions and 0 relapse	17%	15%	No change
Score 1	1 relapse and 0–2 new T2 lesions, or 0 relapse and ⩾3 new T2 lesions	27%	22%	Switch to a DMT with similar efficacy
Score 2	⩾2 relapses, or 1 relapse and ⩾3 new T2 lesions	48%	29%	Switch to a DMT with higher efficacy
DMTs	IFN-βs, fingolimod, natalizumab, DMF, and teriflunomide^81,82
Modified Rio Score⁷⁹
Score 0	new T2 lesions ⩽4 and relapses = 0	NA	24%	NA
Score 1	new T2 lesions ⩽4 and relapses = 1, or new T2 lesions >4 and relapses = 0		33%
Score 2	new T2 lesions ⩽4 and relapses ⩾2, or new T2 lesions >4 and relapses = 1		65%
Score 3	new T2 lesions >4 and relapses ⩾2
DMTs	IFN-βs, fingolimod and natalizumab^79,80

DMT, disease modifying therapy; EDSS, Expanded Disability Status Scale; MAGNIMS, Magnetic Resonance Imaging in Multiple Sclerosis Study Group; MS, Multiple sclerosis; NA, not applicable.

No evidence of disease activity (NEDA) has become the favored treatment goal with the increasing number of DMTs approved in recent years.^83,84 In the CLIMB study, NEDA-3 (no relapses, no sustained progression, and no MRI activity) at 2 years positively predicted 78.3% of patients with a progression-free status (EDSS score change ⩽ 0.5) at 7 years.⁸⁵ In addition, in the EPIC study, NEDA-3 in the first 2 years was not associated with time to EDSS 6 or time to SPMS after a 10-year follow-up.⁸⁶ Meanwhile, it has been very difficult to achieve a good NEDA-3 during RCTs (Table 1), although a high NEDA-3 proportion per year was observed in a real-world setting.^19,41,87 Thus, there is a need to further validate NEDA-3 as a long-term predictor of prognosis.

In 2016, the Magnetic Resonance Imaging in MS (MAGNIMS) score was proposed to assess the response to IFN-β after 1 year of treatment (Table 2).⁸¹ Scores of 0, 1, and 2 could predict the 3-year risk of treatment failure at the rates of 17%, 27%, and 48% (p < 0.001), respectively.⁸¹ Scores of 0, 1, and 2 could also predict the 3-year risk of EDSS worsening at the rates of 15%, 22%, and 29% (p < 0.001), respectively.⁸¹ This scoring system could predict IFN-β treatment failure and EDSS worsening for up to 15 years.⁸⁸ In addition, MAGNIMS score could also predict the response to treatment with other DMTs, such as fingolimod, natalizumab, DMF, and teriflunomide.⁸¹ This scoring system has been cited as a tool for evaluating treatment switching if a suboptimal response is observed.^49,54,64 Therefore, MAGNIMS score may be a suitable and simplified assessment tool for measuring treatment response to DMTs in China. Notably, ⩾2 spinal cord/brainstem lesions indicated a high risk of disease progression, which should be carefully monitored, as mentioned in the 2023 Chinese MS guideline.⁵¹

MS standardized assessment

The regular assessment of MS in China has been published by the Pan-Yangtze River Delta Collaborative Group for Diagnosis and Treatment in Multiple Sclerosis.¹⁷ A comprehensive assessment should be performed, including MRI, neurological functions, such as EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, Symbol Digit Modalities Test, and ophthalmic assessment, including vision, field of vision, optical coherence tomography, and visual-evoked potential. The standardized, comprehensive assessment should be performed at diagnosis and before treatment initiation. Re-baseline and re-assessment should be done every 3–6 months after treatment initiation, and regular assessment should be conducted at least once a year.

DMT switching

None of the available DMTs could completely prevent clinical relapses, MRI activity, and disability progression. When patients show a suboptimal response to the current DMT, switching to another DMT with a different MoA or different efficacy profile should be considered depending on the disease activity, which could be assessed using MAGNIMS score (Table 2).^47,64,89 If patients cannot tolerate the current DMT or have some safety concerns, a switch to a DMT with a different MoA but similar efficacy is highly recommended to maximize the clinical benefits and avoid overtreatment (Figure 2).

The off-label use of DMTs is a global medical issue, existing in at least 89 countries because of the availability and affordability of on-label DMTs.⁹⁰ As mentioned above, corticosteroids, NSIS, were mainly prescribed to patients with MS who received treatment during remission before the approval of oral DMT in China.⁹¹ However, no evidence has shown the long-term benefits of corticosteroids in patients with MS during remission,^92,93 and there are many limitations for treating patients with MS using NSIS regarding the safety concerns, such as cardiotoxicity, severe infections, malignancy, and chromosomal aberrations.⁴⁷ NSIS are usually prescribed for treating patients with highly active MS or aggressive MS,^47,52 which is also recommended in the 2023 Chinese MS guideline.⁵¹ The feasibility of NSIS switching to fundamental DMTs has been proven by clinical trials and real-world studies.^17,94,95 Therefore, patients with not active and active inflammatory MS who are using corticosteroids and NSIS should be switched to the standardized DMT treatment during remission in accordance with disease activity, especially with an increasing number of DMTs approved in China.

De-escalation and discontinuation

There have been very limited data discussing de-escalation and discontinuation, and expert recommendations/guidelines varied in different countries.^47,49,50,54 In 2020, the Canadian MS Working Group mentioned that de-escalation could be taken into consideration in patients on long-term (>5 years) immunosuppressant therapy.⁵⁴ For younger patients (<60 years old) who have been clinically stable for >5 years, de-escalation or discontinuation may cause breakthrough disease activity, so a maintenance therapy should be given in this group.⁵⁴ For older patients (>60 years old), a poorer response to DMTs was observed, whereas there was an increasing risk of side effects, such as infection, due to immunosenescence and comorbidities.^96,97 Clinical trials of DMTs mainly included patients aged 18–55 years old,^98–101 so there is a lack of evidence on efficacy and safety in elderly patients. It is still controversial whether DMTs should be de-escalated or discontinued in elderly MS patients.^{96,97,102–104}

Other factors influencing clinical decision-making

In addition to the clinical benefits, the risk of DMTs should be considered when making clinical decisions. MS can be assessed regularly following the expert recommendation from the Pan-Yangtze River Delta Collaborative Group for Diagnosis and Treatment in Multiple Sclerosis.¹⁰⁵ On the basis of the standardized assessment, a comprehensive evaluation should be performed to provide optimized treatments to MS patients in China.

Pregnancy

Most patients with newly diagnosed MS in China are females aged 30–50 years.⁷ Family planning should be considered when initiating a DMT treatment. So far, only GA can be prescribed to treat patients with RMS during pregnancy in China. DMF exposure (n = 379) during pregnancy did not increase the incidence of birth defects or the rate of spontaneous abortion compared with those in general population.¹⁰⁶ The lack of DMF/MMF accumulation makes it suitable for use until confirmed pregnancy; however, it should still be discontinued during pregnancy itself.¹⁰⁷ Teriflunomide has been associated with teratogenicity from studies on male sperm, which may last up to 2 years after discontinuation.¹⁰⁸ Teriflunomide (pregnancy category X) is contraindicated in pregnant women, and women of childbearing age should use reliable contraception if they are being administered with it.¹⁰⁸ Teriflunomide elimination can be accelerated using cholestyramine or charcoal if required.¹⁰⁹ Data from the Novartis Safety Database reported no congenital anomalies, reports of B-cell depletion, immunoglobulin/hematological abnormalities, or serious infections in MS patients (n = 30) or live births (n = 17) exposed to ofatumumab during pregnancy or 6 months prior to the last menstrual period.¹¹⁰ However, the sample size in that study was small, so caution should be taken when prescribing ofatumumab in female patients with family planning. Moreover, fetal malformation was reported in MS patients treated with fingolimod in the first trimester.¹¹¹

Progressive multifocal leukoencephalopathy

Progressive multifocal leukoencephalopathy (PML) is a rare but severe demyelinating disease of the CNS caused by reactivation of John Cunningham virus.¹¹² It is a serious safety concern for patients who are immunocompromised, as well as for individuals receiving immunosuppressive/modulatory therapy.¹¹² No DMTs in China can be guaranteed to avoid the risk of PML, with the exception of GA. As of 21 July 2021, 12 confirmed PML cases of patients treated with DMF have been recorded, and the PML risk of DMF was reported to be 1.07 per 100,000 patient-years of DMF exposure.¹¹³ As of April 2020, the PML risk of fingolimod was 0.131 per 1000 patient-years.¹¹⁴ Additionally, the PML risk of fingolimod in Japan is higher (estimated 0.652 per 1000 patients) than the worldwide level (0.083 per 1000 patients).¹¹⁵ A suspected PML case caused by teriflunomide has also been reported.¹¹⁶ Leflunomide, whose active metabolite is teriflunomide, has been reported to be associated with PML.¹¹⁷ Moreover, PML cases have been reported in patients taking anti-CD20s.¹¹⁸ Although no PML cases have been found in MS patients taking ofatumumab, cases were reported in patients with chronic lymphocytic leukemia.¹¹⁸ Therefore, irrespective of which DMTs are used, the risk of PML should be carefully monitored and managed.

Rebound

For cell-trafficking DMTs, referred to S1PRMs and natalizumab, treatment cessation may result in the rebound of disease activity.^70,119,120 Rebound activity after the cessation of fingolimod was most commonly mentioned.^119–121 A case report also revealed substantial disease exacerbation after the cessation of siponimod.¹²² The risk of rebound activity should be evaluated when starting the treatment. Management to mitigate this possibility should be planned when switching to treatment with other DMTs.¹²³ A shorter washout period (as short as ⩽7 days) might be a favorable strategy for managing the rebound activity, according to the Japanese post-marketing surveillance of DMF,¹²⁴ The potential risk of PML should be evaluated depending on the subsequent DMTs.¹²⁵

Hepatitis B virus and tuberculosis infections

Hepatitis B virus (HBV) and tuberculosis (TB) infections are more common in China than those in Europe and the US.^126,127 The incidences of acute and chronic HBV infection were reported to be 4.6 and 54.5 per 100,000 person-years in China.¹²⁸ Screening for HBV is required when starting DMT treatment, but only anti-CD20s are contraindicated in HBV infection^129,130 because anti-CD20s increase the risk of mortality caused by HBV reactivation.^131–133 In patients with active HBV, fingolimod cannot be used until resolution of the active phase.¹²⁹ The risk of HBV reactivation of teriflunomide and DMF has not been assessed but is likely to be low.¹²⁹ No publications have reported the risk of HBV reactivation upon the prescription of siponimod and ozanimod due to their short approval time. According to experiences from Italy, patients with MS are suggested to receive HBV vaccination.¹³⁴ Meanwhile, in patients with HBsAb titer negativity or <100 mIU/mL, antiviral prophylaxis is a good way of preventing HBV reactivation,¹³⁴ but drug-drug interaction should also be taken into consideration when prescribing antiviral prophylaxis and DMT simultaneously.

The incidence of TB infection was estimated to be 59 per 100,000 individuals (2020) in China, which is the second highest rate among countries globally.¹²⁷ In this context, two concerns should be raised: (1) The risk of TB reactivation may increase when prescribing DMTs and (2) TB infection may trigger MS.¹³⁵ TB screening should be done when initiating DMTs in MS patients who are at high risk of TB infection.^135–137 DMTs affecting lymphocytes were reported to have a higher risk of indeterminate IFNγ release assay results, a measure for screening TB.¹³⁸ For patients with MS having negative TB results, TB screening should be repeated annually.¹³⁵ Meanwhile, for MS patients with latent TB, DMT initiation should not be delayed until anti-TB treatment has been completed, but clinical and laboratory monitoring should regularly be performed.¹³⁵ Because some anti-TB treatments and DMTs increase the potential risk of drug-induced liver injury,^139,140 drug-drug interaction and TB reactivation should be taken into consideration when making clinical decisions.

Traditional Chinese medicine

Traditional Chinese medicine (TCM) has played an important role in the treatment of various diseases for thousands of years in China. TCMs have been used in Chinese patients with MS (~10%) who received treatment during the remission phase.⁹¹ So far, TCM, acupuncture, moxibustion, tuina, and traditional sports have shown certain effects in the management of MS.¹⁴¹ Yishen Jiedu decoction was proven to reduce the frequency of clinical relapse and prevent EDSS worsening through regulation of T lymphocyte subtypes and IgG.¹⁴² In addition, Yishen Busui Tongluo decoction with methylprednisolone was shown to further improve the symptoms of neurological deficits, Multiple Sclerosis Impact Scale (MSIS-29) scores, and fatigue status compared with methylprednisolone alone during the acute phase.¹⁴³ The combination of acupuncture and herbal decoction also demonstrated favorable effects in MS patients.¹⁴⁴ The integration of Chinese and Western medicine has been explored across several observational studies.^145,146 Therefore, TCM could be considered for the management of both the disease and the symptoms, as well as adverse event management, but drug-drug interaction should also be taken into consideration when planning to integrate Chinese and Western medicine.

Pediatric onset MS

The incidence of pediatric-onset MS (POMS) is 0.055 per 100,000, which is much lower than adults (0.288 per 100,000) in China.⁷ The relapses were more frequent^147,148 and the mental disorders were more common in pediatric patients than in adult patients.^147–149 Early intervention is necessary to prevent disease progression; however, RCTs and regulatory approval of DMT for POMS are lacking. To date, only three DMTs have been approved for POMS: fingolimod by the European Medicines Agency (EMA), U.S. Food and Drug Administration and NMPA, DMF, and teriflunomide by EMA because of the promising efficacy and safety from three RCTs: PARADIGMS, CONNECT, and TERIKIDS.^150–152 In China, fingolimod is the only DMT approved for POMS, which makes the management of POMS difficult. Nevertheless, patients with POMS should still be treated with DMTs as early as possible as per the approved indications and evidence.

Patient preference

MS is a chronic disease that requires long-term management. Patient preference is important for maintaining treatment adherence. Many factors impact treatment adherence, including the route and frequency of administration, intensity of monitoring, cost, and status of reimbursement under health insurance schemes.⁷⁰ There should be an open dialogue between patients and physicians in order to maximize the clinical benefits and patient adherence.^47,55,70

Consideration for future MS treatments in China

The standardized DMT treatment of MS started late in China due to limited DMT availability before 2018. Because MS is defined as a rare disease in China, clinical neurologists in China have limited experience of using DMTs in clinical practice. An algorithm for stratifying patients in terms of disease activity is executable to help clinical neurologists choose a suitable DMT for MS patients. For the first time, we developed a simplified treatment algorithm based on the DMTs available in China, providing reasonable suggestions for treating MS patients in China. This algorithm will help physicians in China treat MS patients appropriately while also helping physicians in other regions who have limited experience of MS management.

Although the eight DMTs cover the full spectrum of efficacy classes from low, medium to high, there was only one high-efficacy monoclonal antibody, ofatumumab, which could not meet the medical needs of MS patients, especially for those with highly active MS. More HETs, such as natalizumab, cladribine, and alemtuzumab, are needed to provide more treatment options to MS patients with highly active MS or poor prognosis.

With the accumulation of clinical experience, personalized treatments will be considered depending on the prognostic factors in future. Recently, a new concept, high-definition medicine, has been proposed,¹⁵³ which involves human beings being treated as a comprehensive system by integrating big personal data at baseline regarding health, genetic risk and genomics, epigenomics, along with cellular, mosaicism, immunome, food, and nutrition tracking, imaging, pharmacogenetics and pharmacogenomics, and artificial intelligence technology, among others. This sophisticated analysis will achieve high-definition prevention and high-precision treatment for MS patients in the future.

Footnotes

Acknowledgements

None.

Declarations

ORCID iDs

Jun Guo

Huan Yang

Chunsheng Yang

Yongfeng Xu

Chao Quan

References

Jia

Zhang

Yang

The incidence and prevalence, diagnosis, and treatment of multiple sclerosis in China: a narrative review. Neurol Sci 2022; 43: 4695–4700.

2022 Drug List of National Medical Insurance, http://www.nhsa.gov.cn/art/2023/1/18/art_104_10078.html (2023, accessed 18 January 2023).

Amin

Hersh

CM.

Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag 2023; 13: 47–70.

Coyle

PK.

The role of natalizumab in the treatment of multiple sclerosis. Am J Manag Care 2010; 16: S164–S170.

Tang

Burns

, et al. BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy. Acta Neuropathol 2022; 143: 505–521.

Qiu

Huang

Hou

, et al.; TOWER Trial Chinese Group. Efficacy and safety of teriflunomide in Chinese patients with relapsing forms of multiple sclerosis: a subgroup analysis of the Phase 3 TOWER Study. Chin Med J 2018; 131: 2776–2784.

Tian

Zhang

Yuan

, et al. Incidence of multiple sclerosis in China: a nationwide hospital-based study. Lancet Reg Health West Pac 2020; 1: 100010.

Liu

Nie

, et al. Prevalence of multiple sclerosis in Guangzhou, China: a population-based case-finding prospective study. Multiple Scler Relat Disord 2022; 68: 104151.

Zhao

Zhang

, et al. Differences in physical, mental, and social functions between males and females in multiple sclerosis: a multicenter cross-sectional study in China. Multiple Scler Relat Disord 2021; 48: 102693.

10.

Guojun

Yan

Weizhi

, et al. A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China. Multiple Scler Relat Disord 2022; 60: 103732.

11.

Zhou

Zeng

Yang

, et al. Status of immunotherapy acceptance in Chinese patients with multiple sclerosis: analysis of Multiple Sclerosis Patient Survival Report 2018. Front Neurol 2021; 12: 651511.

12.

Liu

Wang

, et al. Clinical features and difficulties in diagnosis of multiple sclerosis in China. J Capital Med Univ 2021; 42: 360–366.

13.

Zhang

Yin

Wang

, et al. Clinical outcomes and treatment strategy of multiple sclerosis in China: results from a real-world cross-sectional survey. Chin J Neuroimmunol Neurol 2022; 29: 269–274.

14.

Jia

, et al. Study on disease and economic burden of multiple sclerosis patients in China. China Health Insur 2022; 7: 93–98.

15.

Walton

King

Rechtman

, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Multiple Scler J 2020; 26: 1816–1821.

16.

Lechner-Scott

Spencer

de Malmanche

, et al. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Mult Scler 2012; 18: 974–982.

17.

Prosperini

Mancinelli

Solaro

, et al. Induction versus escalation in multiple sclerosis: a 10-Year Real World Study. Neurother 2020; 17: 994–1004.

18.

Quan

, et al. The effectiveness of teriflunomide in patients with multiple sclerosis in China: a real-world comparison to no DMT treatment in the first year after diagnosis. Ther Adv Neurol Disord 2023; 16: 17562864231181170.

19.

Zhang

Yin

Zhang

, et al. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study. J Neurol 2022; 269: 4808–4816.

20.

Zhang

, et al. Prediction of long-term disability in Chinese patients with multiple sclerosis: a prospective cohort study. Multiple Scler Relat Disord 2020; 46: 102461.

21.

MSBase-Patient demographics, https://msbase.org/data-and-findings/patient-demographics/ (2023, accessed 18 January 2024).

22.

Chun

Zhen

Clinical analysis of 83 patients with multiple sclerosis. Inner Mongolia Med J 2023; 55: 434–438.

23.

Atlas of MS. Estimated proportion of people with MS treated with licensed or off-label Disease Modifying Therapies (DMTs), https://www.atlasofms.org/chart/united-kingdom/disease-modifying-treatments/proportion-of-people-with-ms-treated-with-dmts (2023, accessed 12 October 2023).

24.

Campbell

Simpson

Jr. Ahmad

, et al. Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data. Mult Scler 2020; 26: 1315–1328.

25.

Engelhard

Oleske

Schmitting

, et al. Multiple sclerosis by phenotype in Germany. Multiple Scler Relat Disord 2022; 57: 103326.

26.

Vidal-Jordana

Montalban

Multiple sclerosis: clinical aspects. Curr Opin Neurol 2018; 31: 752–759.

27.

Reich

Lucchinetti

Calabresi

PA.

Multiple sclerosis. N Engl J Med 2018; 378: 169–180.

28.

McGinley

Goldschmidt

Rae-Grant

AD.

Diagnosis and treatment of multiple sclerosis: a review. JAMA 2021; 325: 765–779.

29.

Yong

Chartier

Quandt

Modulating inflammation and neuroprotection in multiple sclerosis. J Neurosci Res 2018; 96: 927–950.

30.

Kieseier

BC.

The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 2011; 25: 491–502.

31.

Racke

Lovett-Racke

Karandikar

NJ.

The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 2010; 74(Suppl. 1): S25–S30.

32.

Gold

Wolinsky

JS.

Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand 2011; 124: 75–84.

33.

U. S. Food and Drug Administration. Durg approval package: Tecfidera (dimethyl fumarate) delayed-release capsules, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063Orig1s000TOC.cfm (2013, accessed 27 March 2023).

34.

van Horssen

Drexhage

Flor

, et al. Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. Free Radic Biol Med 2010; 49: 1283–1289.

35.

Chun

Giovannoni

Hunter

SF.

Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects. Drugs 2021; 81: 207–231.

36.

Montalvao

Garcia

Celli

, et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Investig 2013; 123: 5098–5103.

37.

Multiple Sclerosis Patient Survival Report 2021. Report, China Alliance for Rare Disease, China, 27 February 2021.

38.

Tan

Quan

Interpretation of multiple sclerosis therapy consensus group: position statement on disease-modifying therapies for multiple sclerosis (White Paper). Chin J Clin Neurosci 2023; 31: 428–431.

39.

Lublin

Cofield

Cutter

, et al.; CombiRx Investigators. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013; 73: 327–340.

40.

Freedman

O’Connor

Wolinsky

. Teriflunomide increases the proportion of patients free from disease activity in the TEMSO Phase III Study (PD5.007). Neurology 2012; 78: PD5.007.

41.

Havrdova

Giovannoni

Gold

, et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol 2017; 24: 726–733.

42.

Kappos

Radue

O’Connor

, et al. Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis: results from a phase 3, placebo-controlled study (FREEDOMS). Neurology 2011; 76: A563.

43.

Kappos

Comi

Selmaj

, et al. Evaluating no evidence of disease activity in patients with relapsing multiple sclerosis: post hoc analysis of the Phase 3 RADIANCE and open-label Extension Studies of ozanimod (P7-4.012). Neurology 2022; 98: 839.

44.

Kappos

Fox

Aungst

Longer-term Efficacy of Ofatumumab in Patients with Relapsing Multiple Sclerosis (eRresentations: EPR161). Eur J Neurol 2023; 30: 120–329.

45.

Lublin

Reingold

SC.

Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in multiple sclerosis. Neurology 1996; 46: 907–911.

46.

Lublin

Reingold

Cohen

Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278–286.

47.

Rae-Grant

Day

Marrie

RA.

Author response: practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2019; 92: 110–111.

48.

Niino

Miyazaki

Disease-modifying drugs for multiple sclerosis in Japan: a focus on the 2017 Japanese guidelines and the 2018 supplement. Clin Exp Neuroimmunol 2019; 10: 49–53.

49.

Wiendl

Gold

Berger

, et al.; For the ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord 2021; 14: 17562864211039648.

50.

Mokry

Warnke

Gehring

, et al. Implementation study of the 2021 German guideline for diagnosis and treatment of multiple sclerosis. Multiple Scler Relat Disord 2022; 57: 103434.

51.

Shi

FD.

Chinese society of neuroimmunology. Chinese guidelines for diagnosis and treatment of multiple sclerosis. Chin J Neurol 2024; 57: 10–23.

52.

Rush

MacLean

Freedman

MS.

Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol 2015; 11: 379–389.

53.

Scott

Schramke

CJ.

Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later. J Neurol Sci 2010; 292: 52–56.

54.

Freedman

Devonshire

Duquette

, et al. Treatment optimization in multiple sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci 2020; 47: 437–455.

55.

Montalban

Gold

Thompson

, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018; 24: 96–120.

56.

Matsui

How to use the new 2017 Japanese guidelines for multiple sclerosis and neuromyelitis optica. Clin Exp Neuroimmunol 2017; 8: 351–360.

57.

Polman

Kappos

Freedman

, et al.; BENEFIT investigators. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol 2008; 255: 480–487.

58.

O’Connor

Kinkel

Kremenchutzky

Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. Multiple Scler J 2009; 15: 728–734.

59.

Comi

De Stefano

Freedman

, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012; 11: 33–41.

60.

Comi

Filippi

Barkhof

, et al.; Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576–1582.

61.

Miller

Wolinsky

Kappos

, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 977–986.

62.

Brown

JWL

Coles

Horakova

, et al.; For the MSBase Study Group. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321: 175–187.

63.

Tedeholm

Piehl

Lycke

, et al. Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis. Multiple Scler Relat Disord 2022; 68: 104220.

64.

Le Page

Edan

. Induction or escalation therapy for patients with multiple sclerosis? Rev Neurol 2018; 174: 449–457.

65.

Casanova

Quintanilla-Bordás

C and

Gascón

Escalation

vs.

Early intense therapy in multiple sclerosis. J Pers Med 2022; 12: 104220.

66.

Ontaneda

Tallantyre

Kalincik

, et al. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol 2019; 18: 973–980.

67.

Morgan

Tallantyre

Ontaneda

The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Rev Neurother 2023; 23: 433–444.

68.

Versteegh

Huygens

Wokke

BWH

, et al. Effectiveness and cost-effectiveness of 360 disease-modifying treatment escalation sequences in multiple sclerosis. Value Health 2022; 25: 984–991.

69.

Cree

BAC

Hartung

Barnett

New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol 2022; 35: 262–270.

70.

Rotstein

Montalban

Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 2019; 15: 287–300.

71.

Svenningsson

Frisell

Burman

, et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol 2022; 21: 693–703.

72.

Roos

Hughes

McDonnell

, et al. Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis. JAMA Neurol 2023; 80: 789–797.

73.

Zhao

, et al. Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: a retrospective case series study. Multiple Scler Relat Disord 2023; 70: 104518.

74.

Buron

Chalmer

Sellebjerg

, et al. Comparative effectiveness of teriflunomide and dimethyl fumarate: a nationwide cohort study. Neurology 2019; 92: e1811–e1820.

75.

Braune

Grimm

van Hövell

, et al.; NTD Study Group. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol 2018; 265: 2980–2992.

76.

Ontaneda

Nicholas

Carraro

, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Mult Scler Relat Disord 2019; 27: 101–111.

77.

Kurtzke

JF.

Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

78.

Río

Castilló

Rovira

, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009; 15: 848–853.

79.

Sormani

Rio

Tintorè

, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013; 19: 605–612.

80.

Jamroz-Wiśniewska

Zajdel

Słowik

, et al. Modified rio score with platform therapy predicts treatment success with fingolimod and natalizumab in relapsing-remitting multiple sclerosis patients. J Clin Med 2021; 10: 1830.

81.

Sormani

Gasperini

Romeo

, et al.; MAGNIMS study group. Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology 2016; 87: 134–140.

82.

Kunchok

Lechner-Scott

Granella

, et al.; MSBase Study Group. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Mult Scler 2021; 27: 695–705.

83.

Nixon

Bergvall

Tomic

, et al. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther 2014; 31: 1134–1154.

84.

Smith

Cohen

Hua

LH.

Therapeutic targets for multiple sclerosis: current treatment goals and future directions. Neurother 2017; 14: 952–960.

85.

Rotstein

Healy

Malik

, et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 2015; 72: 152–158.

86.

Cree

BAC

Gourraud

Oksenberg

, et al.; University of California, San Francisco MS-EPIC Team. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016; 80: 499–510.

87.

Prosperini

Lucchini

Haggiag

, et al. Fingolimod vs dimethyl fumarate in multiple sclerosis: a real-world propensity score-matched study. Neurology 2018; 91: e153–e161.

88.

Sormani

Freedman

Aldridge

, et al. MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a. Multiple Scler Relat Disord 2021; 49: 102790.

89.

Peterson

Jalil

Beard

, et al. Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for Multiple Sclerosis: a review. Multiple Scler Relat Disord 2022; 68: 104125.

90.

Laurson-Doube

Rijke

Helme

, et al. Ethical use of off-label disease-modifying therapies for multiple sclerosis. Mult Scler 2021; 27: 1403–1410.

91.

Chinese Society of Neurology. Multiple sclerosis patient survival report 2018. Report, Chinese Society of Neurology, China, 24 February 2019.

92.

Saied

Elsaid

Azab

Long term effects of corticosteroids in multiple sclerosis in terms of the ‘no evidence of disease activity’ (NEDA) domains. Steroids 2019; 149: 108401.

93.

Ciccone

Beretta

Brusaferri

, et al. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev 2008; 23: Cd006264.

94.

Vollmer

Panitch

Bar-Or

, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008; 14: 663–670.

95.

Edan

Comi

Le Page

, et al.; for The French-Italian Mitoxantrone Interferon-beta-1b Trial Group. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry 2011; 82: 1344–1350.

96.

Kalincik

Malpas

Sharmin

Modifiers of the effectiveness of MS immunotherapies (P1421-ECTRIMS 2019). Multiple Scler J 2019; 25: 581–805.

97.

Ostolaza

Corroza

Ayuso

Multiple sclerosis and aging: comorbidity and treatment challenges. Multiple Scler Relat Disord 2021; 50: 102815.

98.

Fox

Miller

Phillips

, et al.; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087–1097.

99.

Hauser

Bar-Or

Cohen

, et al.; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 2020; 383: 546–557.

100.

O’Connor

Wolinsky

Confavreux

, et al.; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293–1303.

101.

Kappos

Radue

O’Connor

, et al.; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.

102.

Vaughn

Jakimovski

Kavak

, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol 2019; 15: 329–342.

103.

Rist

Franklin

RJ.

Taking ageing into account in remyelination-based therapies for multiple sclerosis. J Neurol Sci 2008; 274: 64–67.

104.

Adamczyk-Sowa

Nowak-Kiczmer

Jaroszewicz

, et al. Immunosenescence and multiple sclerosis. Neurol Neurochir Pol 2022; 56: 220–227.

105.

Quan

J-y

Y-f

, et al. Standardized Assessment of Multiple Sclerosis: expert recommendations from the Pan-Yangtze River delta Collaborative Group for diagnosis and treatment in multiple sclerosis (2023). Chin J Clin Neurosci 2023; 31: 241–251.

106.

Hellwig

Rog

McGuigan

, et al. Final analysis of pregnancy outcomes following exposure to dimethyl fumarate in a prospective international registry (S31.004). Neurology 2023; 100: 3843.

107.

Gold

Barnett

Chan

, et al. Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method. Ther Adv Neurol Disord 2023; 16: 17562864231180734.

108.

Cree

BA.

Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Multiple Scler J 2013; 19: 835–843.

109.

Chan

de Seze

Comabella

Teriflunomide in patients with relapsing-remitting forms of multiple sclerosis. CNS Drugs 2016; 30: 41–51.

110.

Bove

Amato

Dobson

, et al. Pregnancy Outcomes in patients with MS following exposure to ofatumumab: updated results from the Novartis Safety Database (P9-3.014). Neurology 2023; 100: 2985.

111.

Karlsson

Francis

Koren

, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014; 82: 674–680.

112.

Bernard-Valnet

Koralnik

Du Pasquier

Advances in treatment of progressive multifocal leukoencephalopathy. Ann Neurol 2021; 90: 865–873.

113.

Lyons

Hughes

McCarthy

, et al. Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate. Mult Scler J Exp Transl Clin 2022; 8: 20552173221132469.

114.

Roman

Hersh

Sillau

Comparative Safety of dimethyl fumarate and fingolimod: findings from the FDA Adverse Event Reporting System (FAERS) (4582). Neurology 2021; 96: 4582.

115.

Nakahara

Tomaske

Kume

, et al. Three cases of non-carryover fingolimod-PML: is the risk in Japan increased? Neurol Neuroimmunol Neuroinflamm 2019; 6: e559.

116.

Lorefice

Fenu

Gerevini

, et al. PML in a person with multiple sclerosis: is teriflunomide the felon? Neurology 2018; 90: 83–85.

117.

Rahmlow

Shuster

Dominik

, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol 2008; 65: 1538–1539.

118.

Sharma

Tolaymat

, et al. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: a review. J Neurol Sci 2022; 443: 120459.

119.

Hatcher

Waubant

Nourbakhsh

, et al. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 2016; 73: 790–794.

120.

Framke

Pontieri

Bramow

, et al. Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in Denmark. J Neurol Neurosurg Psychiatry 2022; 93: 1317–1321.

121.

Coss-Rovirosa

Salado-Burbano

Casallas-Vanegas

, et al. Severe fingolimod rebound syndrome after switching to cladribine treatment. Multiple Scler Relat Disord 2020; 40: 101938.

122.

Litwin

Smoliński Członkowka

Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod. Neurol Neurochir Pol 2018; 52: 98–101.

123.

Barry

Erwin

Stevens

, et al. Fingolimod rebound: a review of the clinical experience and management considerations. Neurol Ther 2019; 8: 241–250.

124.

Yokoyama

Ochi

Fukasawa

Safety and effectiveness of dimethyl fumarate: an interim post-marketing surveillance analysis of Prior DMT Subgroups (P45). Multiple Scler J 2023; 29: n1–n46.

125.

Freedman

Selchen

Prat

, et al. Managing multiple sclerosis: treatment initiation, modification, and sequencing. Can J Neurol Sci 2018; 45: 489–503.

126.

Yue

Zhang

Cai

, et al. Trends in the disease burden of HBV and HCV infection in China from 1990-2019. Int J Infect Dis 2022; 122: 476–485.

127.

Interpretation of Global Tuberculosis Report. 2021, https://tb.chinacdc.cn/zxdt/202110/t20211014_250299.htm (2021, accessed 14 October 2021).

128.

Miao

Wang

Zheng

, et al. Estimation of incidence of viral hepatitis B and analysis on case characteristics in China, 2013-2020. Chin J Endemiol 2021; 42: 1527–1531.

129.

Biolato

Bianco

Lucchini

, et al. The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review. CNS Drugs 2021; 35: 861–880.

130.

Chen

Shao

LY.

Expert consensus on infection management for anti-CD20 monoclonal antibody for the treatment of Neuroimmune Diseases (2022). Chin J Clin Neurosci 2022; 30: 1–7.

131.

Di Bisceglie

Lok

Martin

, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61: 703–711.

132.

Mitka

FDA: increased HBV reactivation risk with ofatumumab or rituximab. JAMA 2013; 310: 1664.

133.

Loomba

Liang

TJ.

Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 2017; 152: 1297–1309.

134.

Buonomo

Viceconte

Calabrese

, et al.; Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. J Neurol 2022; 269: 3301–3307.

135.

Navas

Torres-Duque

Munoz-Ceron

, et al. Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis. Mult Scler J Exp Transl Clin 2018; 4: 2055217317752202.

136.

Dantas

Pereira

Gauza

, et al. Latent tuberculosis infection reactivation in patients with multiple sclerosis in use of disease-modifying therapies: a systematic review. Multiple Scler Relat Disord 2021; 55: 103184.

137.

Bouley

Baber

Egnor

, et al. Prevalence of latent tuberculosis in the multiple sclerosis clinic and effect of multiple sclerosis treatment on tuberculosis testing. Int J MS Care 2021; 23: 26–30.

138.

Baldassari

Feng

Macaron

, et al. Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting. Mult Scler J Exp Transl Clin 2019; 5: 2055217319875467.

139.

Antonazzo

Poluzzi

Forcesi

, et al. Liver injury with drugs used for multiple sclerosis: a contemporary analysis of the FDA Adverse Event Reporting System. Mult Scler 2019; 25: 1633–1640.

140.

Ramappa

Aithal

GP.

Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol 2013; 3: 37–49.

141.

Tang

Peng

Nie

Current situation and reflection of traditional Chinese medicine in the treatment of multiple sclerosis. World Chin Med 2023; 18: 583–587. 592.

142.

Lin

Kuang

Effects of compound Yishen Jiedu decoction on RRMS patients in remission period of the clinical efficacy and immunological indicators T lymphocyte subsets and immunoglobulin before and after treatment. Jilin J Chin Med 2019; 39: 1598–1601.

143.

Han

Effect of Yishen Busui Tongluo decoction with methylprednisolone on multiple sclerosis and its effect on the expression of inflammatory factors and HMGB1. Modern J Integr Trad Chin West Med 2019; 28: 4012–4016.

144.

Cui

Chen

Hong

, et al. Clinical Research on treatment of multiple sclerosis with acupuncture and Herbal Decoction. Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai 2013; 27: 48–50.

145.

Liu

Clinical analysis of combined Chinese and Western medicine in treatment of 60 cases of multiple sclerosis. China Med Pharmacy 2014; 5: 108–109.

146.

Wang

Qian

Clinical observation on 163 cases of multiple sclerosis treated by integrative medicine. Contemp Med Forum 2009; 22: 44–45.

147.

Gorman

Healy

Polgar-Turcsanyi

, et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009; 66: 54–59.

148.

Yeh

Weinstock-Guttman

Ramanathan

, et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain 2009; 132: 3392–3400.

149.

Solmi

Radua

Olivola

, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry 2022; 27: 281–295.

150.

Chitnis

Arnold

Banwell

, et al.; PARADIGMS Study Group. Trial of fingolimod versus Interferon beta-1a in pediatric multiple sclerosis. N Engl J Med 2018; 379: 1017–1027.

151.

Vermersch

Scaramozza

Levin

, et al. Effect of dimethyl fumarate vs interferon β-1a in patients with pediatric-onset multiple sclerosis: the CONNECT Randomized Clinical trial. JAMA Netw Open 2022; 5: e2230439.

152.

Chitnis

Banwell

Kappos

, et al.; TERIKIDS Investigators. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol 2021; 20: 1001–1011.

153.

Torkamani

Andersen

Steinhubl

, et al. High-definition medicine. Cell 2017; 170: 828–843.

Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China

Abstract

Plain language summary

Keywords

Introduction

Characteristics of MS patients in China

Demographics

DMT usage

Initiation of RMS treatment in China

Disease activity

Early initiation

Treatment options

Treatment switching

Treatment response

MS standardized assessment

DMT switching

De-escalation and discontinuation

Other factors influencing clinical decision-making

Pregnancy

Progressive multifocal leukoencephalopathy

Rebound

Hepatitis B virus and tuberculosis infections

Traditional Chinese medicine

Pediatric onset MS

Patient preference

Consideration for future MS treatments in China

Footnotes

Acknowledgements

Declarations

ORCID iDs

References